Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
11 - 20 out of 159Page size: 10
Sort by: 1st author
  1. Published

    New pathogenic germline variants identified in mesothelioma

    Belcaid, L., Bertelsen, B., Wadt, Karin Anna Wallentin, Tuxen, I., Spanggaard, I., Højgaard, M., Sørensen, Jens Benn, Ravn, J., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Rohrberg, K. & Westmose Yde, C., 2023, In: Lung Cancer. 179, 8 p., 107172.

    Research output: Contribution to journal › Review › Research › peer-review

  2. Published

    High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

    Bertelsen, B., Tuxen, I. V., Yde, C. W., Gabrielaite, M., Torp, M. H., Kinalis, S., Oestrup, O., Rohrberg, K., Spangaard, I., Santoni Rugiu, Eric, Wadt, Karin Anna Wallentin, Mau-Sorensen, M., Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2019, In: npj Genomic Medicine. 4, 1, 11 p., 13.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Putting data to work for precision medicine

    Bjerrum, A. & Lassen, Ulrik Niels, 2023, In: Cell Reports Medicine. 4, 7, 3 p., 101090.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  4. Published

    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

    Bono, P., Massard, C., Peltola, K. J., Azaro, A., Italiano, A., Kristeleit, R. S., Curigliano, G., Lassen, Ulrik Niels, Arkenau, H. T., Hakulinen, P., Garratt, C., Ikonen, T., Mustonen, M. V. J. & Rodon, J. A., 2020, In: ESMO Open. 5, 6, 11 p., e001081.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

    Borch, A., Bjerregaard, A. M., Araujo Barbosa de Lima, V., Østrup, O., Yde, C. W., Eklund, A. C., Mau-Sørensen, M., Barra, C., Svane, Inge Marie, Nielsen, Finn Cilius, Funt, S. A., Lassen, Ulrik Niels & Hadrup, S. R., 2023, In: Frontiers in Genetics. 14, 13 p., 1058605.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

    Borghaei, H., Alpaugh, K., Hedlund, G., Forsberg, G., Langer, C., Rogatko, A., Hawkins, R., Dueland, S., Lassen, Ulrik Niels & Cohen, R. B., 2009, In: Journal of Clinical Oncology. 27, 25, p. 4116-23 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study

    Briggs, A., Paracha, N., Rosettie, K., Upton, A., Bokemeyer, C., Lassen, Ulrik Niels & Sullivan, S. D., Jan 2022, In: Oncology. 100, 2, p. 124–129 6 p.

    Research output: Contribution to journal › Letter › Research › peer-review

  8. Published

    Changes in key recruitment performance metrics from 2008-2019 in industrysponsored phase III clinical trials registered at ClinicalTrials.gov

    Brøgger-Mikkelsen, Mette, Zibert, J. R., Andersen, A. D., Lassen, Ulrik Niels, Hædersdal, Merete, Ali, Z. & Thomsen, Simon Francis, 2022, In: PLoS ONE. 17, 7 July, p. 1-15 e0271819.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

    Carlson, J. J., Italiano, A., Brose, M. S., Federman, N., Lassen, Ulrik Niels, Kummar, S. & Sullivan, S. D., 2022, In: American Journal of Managed Care. 28, p. S26-S32

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    Cejalvo, J. M., Jacob, W., Fleitas Kanonnikoff, T., Felip, E., Navarro Mendivil, A., Martinez Garcia, M., Taus Garcia, A., Leighl, N., Lassen, Ulrik Niels, Mau-Soerensen, M., Adessi, C., Michielin, F., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2019, In: ESMO Open. 4, 4, 7 p., e000532.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 5 6 7 8 ...16 Next

ID: 4952653